Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15630864 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3IDO1 | |
| SCHEMBL15630865 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3IDO1 | |
| SCHEMBL34468451 | 0.98 | MDM4 (0.54) | MDM4TP53MDM2CASP3IDO1 | |
| SCHEMBL5969952 | 0.94 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL16059782 | 0.90 | MDM2 (0.55) | MDM4TP53MDM2CASP3 | |
| SCHEMBL28306682 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3IDO1 | |
| SCHEMBL30945050 | 0.89 | MDM4 (0.60) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29091196 | 0.89 | MDM4 (0.60) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL8897778 | 0.89 | MDM4 (0.60) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL16059779 | 0.89 | MDM2 (0.58) | MDM4TP53MDM2CASP3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410228-B2 | Insulin analogs | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-09-09 | — | — | US | disclosed |
| US-20240209432-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4303314-A2 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | F. Hoffmann-La Roche AG (CH) | 2024-01-10 | — | — | EP | disclosed |
| CN-116874584-A | Insulin analogues | 犹他大学研究基金会 | 2023-10-13 | — | — | CN | disclosed |
| US-11739378-B2 | Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection | Roche Sequencing Solutions, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-110072884-B | Insulin analogues | 犹他大学研究基金会 | 2023-07-28 | — | — | CN | disclosed |
| US-20220340636-A1 | INSULIN ANALOGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2022-10-27 | — | — | US | disclosed |
| US-20220090189-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2022-03-24 | — | — | US | disclosed |
| CN-108350017-B | Polypeptide-labeled nucleotides and their use in nucleic acid sequencing by nanopore detection | 豪夫迈·罗氏有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11248034-B2 | Insulin analogs | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-10400010-B2 | Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2994476-B1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS | UNIV CALIFORNIA (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20180155396-A1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739378-B2 | Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection | NPPA, ANPEP, TENT4A | MDM4 1047/4885TP53 447/4885MDM2 3649/4885 |
| US-20220090189-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | NPPA, ANPEP, TENT4A | MDM4 1047/4885TP53 447/4885MDM2 3649/4885 |
| US-20180155396-A1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS | TP53, TP53BP1, API5 | MDM4 4/4885TP53 1/4885MDM2 7/4885 |
| US-20240209432-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | NPPA, ANPEP, TENT4A | MDM4 1047/4885TP53 447/4885MDM2 3649/4885 |
| US-10400010-B2 | Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics | TP53, TP53BP1, API5 | MDM4 4/4885TP53 1/4885MDM2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.